The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.
 
Enriqueta Felip
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer; Roche
 
Matthew David Hellmann
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Janssen; Merck; Novartis
Research Funding - Bristol-Myers Squibb
 
Rina Hui
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer
Consulting or Advisory Role - AstraZeneca; MSD; Novartis; Pfizer
 
Enric Carcereny
No Relationships to Disclose
 
Natasha B. Leighl
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; MSD
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; MSD
 
Joseph Paul Eder
Research Funding - AstraZeneca (Inst)
 
Ani Sarkis Balmanoukian
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Genentech; Merck
 
Charu Aggarwal
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Genentech; Lilly
Research Funding - Genentech/Roche (Inst); Incyte (Inst); Macrogenics (Inst); Merck Sharp & Dohme (Inst)
 
Leora Horn
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genentech; Janssen; Lilly; Merck; Xcovery
Research Funding - Boehringer Ingelheim (Inst); Xcovery (Inst); Xcovery (Inst)
Other Relationship - Boehringer Ingelheim; Bristol-Myers Squibb
 
Amita Patnaik
Consulting or Advisory Role - Bayer
Research Funding - Abbvie; Aeglea Biotherapeutics; Alexion Pharmaceuticals; Amgen; Asana Biosciences; Ascentage Pharma Group; Astex Pharmaceuticals; AVEO (Inst); Bayer; Bayer (Inst); Calithera Biosciences; Celgene (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Endocyte (Inst); Five Prime Therapeutics (Inst); Formation Biologics (Inst); Forty Seven; Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jiangsu Hengrui Medicine; Jiangsu Hengrui Medicine (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Merck Sharp & Dohme; Novartis; OncoMed; Pfizer (Inst); Plexxikon; Plexxikon (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst); Tesaro (Inst); Tesaro (Inst); Teva (Inst); Upsher-Smith; Zymeworks (Inst)
 
Matthew A. Gubens
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Mersana; Novartis
Research Funding - Celgene (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); OncoMed (Inst)
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Merck; Takeda
Travel, Accommodations, Expenses - AstraZeneca; EMD Serono; Pfizer
 
Erin Jensen
Employment - Merck Sharp & Dohme
 
Debra A. Kush
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Edward B. Garon
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)